

OGN/Osteoglycin Protein, Human, Recombinant (His)

General Information

Synonyms:	OIF;OG;osteoglycin;SLRR3A
Protein Construction:	A DNA sequence encoding the human OGN (NP_054776.1) (Met1-Phe298) was expressed with a polyhistidine tag at the C-terminus. Predicted N terminal: Pro 21
Species:	Human
Expression Host:	HEK293 Cells
Accession:	P20774
Molecular Weight:	33.2 kDa (predicted)

QC Testing

Biological Activity:	Activity testing is in progress. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first.
Purity:	> 95 % as determined by SDS-PAGE.
Endotoxin:	< 1.0 EU/μg of the protein as determined by the LAL method.
Formulation:	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS, pH 7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization.

Preparation and Storage

Reconstitution:
A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.

Stability & Storage:
It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Actual storage temperature shall be subject to the COA.

Shipping:
In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.

Protein Background

OGN (Osteoglycin) is a Protein Coding gene. This gene encodes a member of the small leucine-rich proteoglycan (SLRP) family of proteins. It belongs to the small leucine-rich proteoglycan (SLRP) family. The encoded protein induces ectopic bone formation in conjunction with transforming growth factor-beta and may regulate osteoblast differentiation. OGN is broadly expressed in the gall bladder, endometrium, and other tissues. OGN reduced Zeb-1 expression via EGFR/Akt leading to inhibition of epithelial-mesenchymal transition. In vitro and in vivo, the OGN

A DRUG SCREENING EXPERT

expression was demonstrated to reduce cell proliferation, inhibit invasion of colon cancer cells then impede cancer progression. Diseases associated with OGN include Inhibited Male Orgasm and Cornea Plana.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481